Change Healthcare Inc. Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results

Rhea-AI Summary

Change Healthcare reported strong financial results for Q4 2022, achieving $920 million in total revenue, an increase from $855.2 million in Q4 2021. Solutions revenue rose by 6.8% to $859.2 million, driven by increased volume and COVID-19 activities. The company posted a net income of $7.1 million, compared to a loss of $13.1 million in the previous year. Adjusted EBITDA grew by 3.8% to $282.3 million. Cash flow from operations reached $696.9 million, with free cash flow at $420.6 million, a 23.8% increase from fiscal 2021.

Positive

• Solutions revenue grew by 6.8% to $859.2 million, driven by volume increases and COVID-19 initiatives.
• Net income improved to $7.1 million from a previous loss of $13.1 million.
• Adjusted EBITDA increased by 3.8% to $282.3 million.
• Free cash flow rose by 23.8%, reaching $420.6 million.

Negative

• Guidance is no longer provided due to the pending merger with OptumInsight.

• Strong revenue and cash flow growth driven by continued momentum in core business and investment in expanded capabilities
• Total revenue of $920M, including record solutions revenue of $859M; solutions revenue growth of 6.8% driven by increased volume, COVID-19 activities and new sales

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Change Healthcare Inc. (Nasdaq: CHNG) (the “Company” or “Change Healthcare”), a leading healthcare technology company, today reported financial results for the fourth quarter and fiscal year ended March 31, 2022.

“The fourth quarter performance demonstrates the execution of our growth strategy, delivering on our financial objectives while continuing to make investments to advance our capabilities and support our customers and employees,” said Neil de Crescenzo, president and chief executive officer. “As we enter fiscal 2023, we remain focused on developing and delivering innovative solutions for healthcare providers, payers, partners and consumers to improve clinical, financial, and care outcomes.”

Fiscal 2022 Fourth Quarter Highlights:

Recent Business Highlights

• Signed a strategic partnership with Luma Health that will utilize Luma's KLAS-recognized Healthcare Engagement Engine™ alongside Change Healthcare’s proven revenue cycle capabilities to develop new patient engagement solutions that seamlessly connect every touchpoint across the patient journey.
• Integrated predictive analytics into InterQual AutoReview, enabling the solution to apply artificial intelligence to real-time EHR data and provide data-driven predictions on which level of care status is right for each patient.
• Awarded “Best in KLAS” for Payer IT Consulting Services for the third time in four years.

Impact of McKesson Exit on Comparability of Results

On March 10, 2020, Change Healthcare Inc. acquired the interest in Change Healthcare LLC (“the Joint Venture”) previously held by McKesson. The transaction resulted in Change Healthcare Inc. acquiring control of the Joint Venture, which was accounted for as a business combination resulting in fair value adjustments to various assets and liabilities, including deferred revenue, goodwill, and intangible assets.

Financial Results for Fourth Quarter of Fiscal 2022

	Q4 2022	Q4 2021
Total Revenue1	$920.1 million	$855.2 million
Solutions Revenue1	$859.2 million	$804.3 million
Net Income (Loss)	$7.1 million	$(13.1) million
Diluted EPS2	$0.02	$(0.04)
Adjusted EBITDA	$282.3 million	$272.0 million
Adjusted Net Income	$130.3 million	$134.0 million
Adjusted Diluted EPS2	$0.39	$0.42

1. Total Revenue and Solutions Revenue for fourth quarter of fiscal 2021 included the impact of fair value adjustments to deferred revenue resulting from the McKesson exit, which reduced revenue recognized by $10.1 million.

2. Diluted EPS and Adjusted Diluted EPS for the current period are based on 331 million shares compared to 321 million shares in the fourth quarter of fiscal 2021.

Solutions revenue in the fourth quarter grew 6.8% compared to the fourth quarter of fiscal 2021, driven by volume growth and incremental revenue from COVID-19 testing and new sales. Adjusted EBITDA grew 3.8% over the same period, reflecting the aforementioned revenue growth, partially offset by investments to support business initiatives.

Cash Flow and Balance Sheet Highlights

Net cash provided by operating activities was $696.9 million and free cash flow was $420.6 million, in each case, for the twelve months ended March 31, 2022. For the twelve months ended March 31, 2021, net cash provided by operating activities and free cash flow were $586.2 million and $339.8 million, respectively. Free cash flow increased 23.8% in the current year compared to fiscal 2021.

Net cash provided by operating activities and free cash flow each are affected by pass-thru funds we receive from certain pharmaceutical industry participants in advance of our obligation to remit these funds to participating retail pharmacies. Such pass-thru funds on hand increased by $12.9 million in the twelve months ended March 31, 2022, increasing free cash flow for the period by that amount, and decreased by $12.8 million for the twelve months ended March 31, 2021.

The Company ended the quarter with approximately $252.3 million of cash and cash equivalents, and approximately $4,590.1 million of total debt. Subsequent to the end of the quarter, the Company repaid $100.0 million of its Senior Notes.

Guidance

Due to the proposed transaction with OptumInsight, we will no longer be providing financial guidance.

Update on Proposed Merger with OptumInsight

On January 5, 2021, OptumInsight, a diversified health services company and part of UnitedHealth Group, and Change Healthcare agreed to combine (the “Merger”). Under the terms of the merger agreement, UnitedHealth Group, through a wholly-owned subsidiary, will acquire all of the outstanding shares of Change Healthcare common stock for $25.75 per share in cash. The Boards of Directors of both UnitedHealth Group and Change Healthcare have unanimously approved the terms of the Merger, and Change Healthcare stockholders voted to approve the Merger on April 13, 2021. The closing of the Merger is subject to applicable regulatory approval and other customary closing conditions.

On February 24, 2022, the Department of Justice (“DOJ”) and certain other parties commenced litigation to block the Merger, and the Company continues to support UnitedHealth Group in working toward closing the Merger. On April 4, 2022, the parties to the merger agreement entered into a waiver pursuant to which, among other things, Change Healthcare and UnitedHealth Group each waived its right to terminate the merger agreement until the earlier of (i)the tenth business day following a final order issued by the U.S. District Court for the District of Columbia with respect to the complaint filed by the DOJ that prohibits the consummation of the Merger and (ii) December 31, 2022. OptumInsight will pay a $650 million fee to Change Healthcare in the event the Merger is unable to be completed because of the decision issued by the U.S. District Court for the District of Columbia upon completion of the trial that is scheduled to begin on August 1, 2022.

Additionally, the Company will be permitted to declare and pay a one-time special dividend of up to $2.00 in cash per each issued and outstanding share of its common stock, with a record date and payment date to be determined in the sole discretion of the Company’s Board of Directors (or a committee thereof). The Company expects to pay the dividend at or about the time of closing the Merger.

On April 22, 2022, UnitedHealth Group, as seller, entered into an equity purchase agreement and related agreements relating to the sale of the Company’s claims editing business to an affiliate of investment funds of TPG Capital for a base purchase price in cash equal to $2.2 billion (subject to customary adjustments). Consummation of the transaction is contingent on a number of conditions, including the consummation of the Merger.

Webcast Information

Change Healthcare will host a conference call on Thursday, May 26, 2022, at 8:00 a.m. ET. Due to the previously announced transaction with OptumInsight, the Company will not be taking questions during the conference call.

Investors and other interested parties are invited to listen to the conference call via the Company's website at https://ir.changehealthcare.com/. The webcast will be available for on-demand listening at the aforementioned URL until May 26, 2023.

About Change Healthcare

Change Healthcare (Nasdaq: CHNG) is a leading healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system. Learn more at changehealthcare.com.

CHNG-IR

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations and businesses of Change Healthcare. Some of these statements can be identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “could,” “should,” “may,” “plan,” “project,” “predict” and similar expressions. Change Healthcare cautions readers of this press release that such “forward looking statements,” including without limitation, those relating to the timing of the proposed merger and Change Healthcare’s future business prospects, revenue, working capital, liquidity, capital needs, interest costs and income, wherever they occur in this press release or in other statements attributable to Change Healthcare, are necessarily estimates reflecting the judgment of Change Healthcare’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward looking statements.”

Factors that could cause Change Healthcare’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to, the inability to complete the proposed merger due to the failure to satisfy the conditions to the completion of the proposed merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; risks related to disruption of management’s attention from Change Healthcare’s ongoing business operations due to the transaction; the effect of the announcement of the proposed merger on Change Healthcare’s operations, results and business generally; the risk that the proposed merger will not be consummated in a timely manner, exceeding the expected costs of the merger; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; macroeconomic and industry trends and adverse developments in the debt, consumer credit and financial services markets; uncertainty and risks related to the impact of the COVID-19 pandemic (including the rise of COVID-19 variant strains such as the Delta and Omicron variants) on the national and global economy, Change Healthcare’s business, suppliers, customers, and employees; Change Healthcare’s ability to retain and recruit key management personnel and other talent (including while the proposed merger is pending); Change Healthcare’s ability to retain or renew existing customers and attract new customers; Change Healthcare’s ability to connect a large number of payers and providers; Change Healthcare’s ability to provide competitive services and prices while maintaining its margins; further consolidation in Change Healthcare’s end-customer markets; Change Healthcare’s ability to effectively manage its costs; Change Healthcare’s ability to effectively develop and maintain relationships with its channel partners; Change Healthcare’s ability to timely develop new services and improve existing solutions; Change Healthcare’s ability to deliver services timely without interruption; a decline in transaction volume in the U.S. healthcare industry; Change Healthcare’s ability to maintain access to its data sources; Change Healthcare’s ability to maintain the security and integrity of its data; Change Healthcare’s reliance on key management personnel; Change Healthcare’s ability to manage and expand its operations and keep up with rapidly changing technologies; the ability of outside service providers and key vendors to fulfill their obligations to Change Healthcare; risks related to international operations; Change Healthcare’s ability to protect and enforce its intellectual property, trade secrets and other forms of unpatented intellectual property; Change Healthcare’s ability to defend its intellectual property from infringement claims by third parties; government regulation and changes in the regulatory environment; changes in local, state, federal and international laws and regulations, including related to taxation; economic and political instability in the U.S. and international markets where Change Healthcare operates; the economic impact of escalating global tensions, including the conflict between Russia and Ukraine, and the adoption or expansion of economic sanctions or trade restrictions; litigation or regulatory proceedings; losses against which Change Healthcare does not insure; Change Healthcare’s ability to make acquisitions and integrate the operations of acquired businesses; Change Healthcare’s ability to make timely payments of principal and interest on its indebtedness; Change Healthcare’s ability to satisfy covenants in the agreements governing its indebtedness; Change Healthcare’s ability to maintain liquidity; the potential dilutive effect of future issuance of shares of Change Healthcare’s common stock; the impact of anti-takeover provisions in Change Healthcare’s organizational documents and under Delaware law, which may discourage or delay acquisition attempts; Change Healthcare’s adoption of new, or amendments to existing, accounting standards, and other risks. For a more detailed discussion of these factors, see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Change Healthcare’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 27, 2021 as such factors may be updated from time to time in our periodic filings with the SEC.

Change Healthcare’s forward-looking statements speak only as of the date of this press release or as of the date they are made. Change Healthcare disclaims any intent or obligation to update any “forward looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

Non-GAAP Financial Measures

In the Company’s earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. We believe such measures provide supplemental information to investors with regards to our operating performance and assist investors’ ability to compare our financial results to those of other companies in the same industry. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this press release after the consolidated financial statements. These non-GAAP financial measures are calculated and presented on the basis of methodologies other than in accordance with GAAP. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP and may be defined and calculated differently by others in the same industry.

Consolidated Statements of Operations (unaudited and amounts in thousands, except share and per share amounts)
		Three Months Ended March 31,
		2022			2021
Revenue:
Solutions revenue		$	859,194		$	804,299
Postage revenue			60,937			50,861
Total revenue			920,131			855,160
Operating expenses:
Cost of operations (exclusive of depreciation and amortization below)			362,459			357,506
Research and development			72,306			58,926
Sales, marketing, general and administrative			186,288			187,606
Customer postage			60,937			50,861
Depreciation and amortization			179,345			154,495
Accretion and changes in estimate with related parties, net			5,967			2,744
Gain on sale of businesses			—			1,344
Total operating expenses			867,302			813,482
Operating income (loss)			52,829			41,678
Non-operating (income) and expense
Interest expense, net			56,959			59,508
Loss on extinguishment of debt			—			1,289
Other, net			2,078			(2,253)
Total non-operating (income) and expense			59,037			58,544
Income (loss) before income tax provision (benefit)			(6,208)			(16,866)
Income tax provision (benefit)			(13,298)			(3,776)
Net income (loss)		$	7,090		$	(13,090)
Net income (loss) per common share:
Basic		$	0.02		$	(0.04)
Diluted		$	0.02		$	(0.04)
Weighted average common shares outstanding:
Basic			325,002,702			321,393,600
Diluted			330,822,467			321,393,600

Consolidated Statements of Operations (unaudited and amounts in thousands, except share and per share amounts)
		Year Ended March 31,
		2022			2021
Revenue:
Solutions revenue		$	3,261,203		$	2,893,889
Postage revenue			219,612			196,532
Total revenue			3,480,815			3,090,421
Operating expenses:
Cost of operations (exclusive of depreciation and amortization below)			1,415,267			1,335,075
Research and development			277,930			227,036
Sales, marketing, general and administrative			734,554			686,645
Customer postage			219,612			196,532
Depreciation and amortization			681,808			591,048
Accretion and changes in estimate with related parties, net			14,833			13,158
Gain on sale of businesses			—			(59,143)
Total operating expenses			3,344,004			2,990,351
Operating income (loss)			136,811			100,070
Non-operating (income) and expense
Interest expense, net			234,244			245,241
Loss on extinguishment of debt			3,885			8,924
Other, net			4,683			(6,698)
Total non-operating (income) and expense			242,812			247,467
Income (loss) before income tax provision (benefit)			(106,001)			(147,397)
Income tax provision (benefit)			(48,611)			(35,187)
Net income (loss)		$	(57,390)		$	(112,210)
Net income (loss) per common share:
Basic and diluted		$	(0.18)		$	(0.35)
Weighted average common shares outstanding:
Basic and diluted			323,996,600			320,771,789

Consolidated Balance Sheets (unaudited and amounts in thousands, except share and per share amounts)
		March 31, 2022			March 31, 2021
Assets
Current assets:
Cash and cash equivalents		$	252,298		$	113,101
Accounts receivable, net			720,122			732,614
Contract assets, net			162,828			132,856
Prepaid expenses and other current assets			177,659			140,258
Total current assets			1,312,907			1,118,829
Property and equipment, net			141,340			174,370
Operating lease right-of-use assets, net			65,680			93,412
Goodwill			4,112,904			4,108,792
Intangible assets, net			3,699,603			4,187,072
Other noncurrent assets, net			600,061			430,141
Total assets		$	9,932,495		$	10,112,616
Liabilities
Current liabilities:
Accounts payable		$	104,273		$	57,449
Accrued expenses			461,506			484,293
Deferred revenue			469,098			436,666
Due to related parties, net			13,057			10,766
Current portion of long-term debt			10,006			27,339
Current portion of operating lease liabilities			21,726			30,608
Total current liabilities			1,079,666			1,047,121
Long-term debt, excluding current portion			4,580,087			4,734,775
Long-term operating lease liabilities			52,286			75,396
Deferred income tax liabilities			563,606			605,291
Tax receivable agreement obligations to related parties			104,863			103,151
Tax receivable agreement obligations			202,762			229,082
Other long-term liabilities			73,118			65,572
Total liabilities			6,656,388			6,860,388
Commitments and contingencies
Stockholders' Equity
Common Stock (par value, $0.001), 9,000,000,000 and 9,000,000,000 shares authorized and 313,131,714 and 306,796,076 shares issued and outstanding at March 31, 2022 and March 31, 2021, respectively			313			307
Preferred stock (par value, $0.001), 900,000,000 shares authorized and no shares issued and outstanding at both March 31, 2022 and March 31, 2021			—			—
Additional paid-in capital			4,340,759			4,283,391
Accumulated other comprehensive income (loss)			35,116			11,221
Accumulated deficit			(1,100,081)			(1,042,691)
Total stockholders' equity			3,276,107			3,252,228
Total liabilities and stockholders' equity		$	9,932,495		$	10,112,616

Consolidated Statements of Cash Flows (unaudited and amounts in thousands)
		Year Ended March 31,
		2022			2021
Cash flows from operating activities:
Net income (loss)		$	(57,390)		$	(112,210)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			681,808			591,048
Amortization of capitalized software developed for sale			3,509			1,326
Accretion and changes in estimate, net			25,276			11,644
Equity compensation			95,730			59,016
Deferred income tax expense (benefit)			(49,060)			(50,114)
Amortization of debt discount and issuance costs			31,284			32,532
Loss on extinguishment of debt			3,885			8,924
Non-cash lease expense			26,648			29,114
Gain on sale of businesses			—			(59,143)
Other, net			17,658			8,257
Changes in operating assets and liabilities:
Accounts receivable, net			12,295			(6,064)
Contract assets, net			(26,114)			158
Prepaid expenses and other assets			(82,507)			(87,540)
Accounts payable			34,825			(21,407)
Accrued expenses and other liabilities			(61,032)			14,178
Deferred revenue			40,063			166,477
Net cash provided by (used in) operating activities			696,878			586,196
Cash flows from investing activities:
Capitalized expenditures			(276,276)			(246,381)
Acquisitions, net of cash acquired			—			(439,483)
Proceeds from sale of businesses			—			115,733
Other, net			(663)			2,099
Net cash provided by (used in) investing activities			(276,939)			(568,032)
Cash flows from financing activities:
Payments on Term Loan Facility			(180,000)			(315,000)
Payments under tax receivable agreements			(21,537)			(20,691)
Receipts (payments) on derivative instruments			(22,709)			(29,538)
Employee tax withholding on vesting of equity compensation awards			(37,751)			(4,108)
Payments on deferred financing obligations			(10,991)			(19,519)
Payment of senior amortizing notes			(16,384)			(15,636)
Proceeds from exercise of equity awards			8,933			17,514
Payments on Revolving Facility			—			(250,000)
Proceeds from issuance of Senior Notes			—			325,000
Other, net			(468)			(6,800)
Net cash provided by (used in) financing activities			(280,907)			(318,778)
Effect of exchange rate changes on cash and cash equivalents			165			3,310
Net increase (decrease) in cash and cash equivalents			139,197			(297,304)
Cash and cash equivalents at beginning of period			113,101			410,405
Cash and cash equivalents at end of period		$	252,298		$	113,101

Reconciliation of Net Income (Loss) to Adjusted EBITDA (unaudited and amounts in thousands)
		Three Months Ended March 31,
		2022			2021
Net income (loss)		$	7,090		$	(13,090)
Income tax provision (benefit)			(13,298)			(3,776)
Income (loss) before income tax provision (benefit)			(6,208)			(16,866)
Amortization of capitalized software developed for sale			999			776
Depreciation and amortization			179,345			154,495
Interest expense, net			56,959			59,508
Equity compensation			21,012			24,158
Acquisition accounting adjustments			(4,762)			5,917
Acquisition and divestiture-related costs			12,254			9,590
Integration and related costs			3,608			13,094
Strategic initiatives, duplicative and transition costs			7,977			8,671
Severance costs			(4,484)			2,717
Accretion and changes in estimate, net			11,706			3,215
Impairment of long-lived assets and other			728			3,772
Loss on extinguishment of debt			—			1,289
Gain on sale of business			—			1,344
Other non-routine, net			3,189			365
Adjusted EBITDA		$	282,323		$	272,045

Reconciliation of Net Income (Loss) to Adjusted EBITDA (unaudited and amounts in thousands)
		Year Ended March 31,
		2022			2021
Net income (loss)		$	(57,390)		$	(112,210)
Income tax provision (benefit)			(48,611)			(35,187)
Income (loss) before income tax provision (benefit)			(106,001)			(147,397)
Amortization of capitalized software developed for sale			3,509			1,326
Depreciation and amortization			681,808			591,048
Interest expense, net			234,244			245,241
Equity compensation			95,730			59,016
Acquisition accounting adjustments			(11,839)			109,743
Acquisition and divestiture-related costs			41,120			19,709
Integration and related costs			26,803			40,675
Strategic initiatives, duplicative and transition costs			46,041			21,841
Severance costs			10,178			13,184
Accretion and changes in estimate, net			25,276			11,644
Impairment of long-lived assets and other			4,958			18,190
Loss on extinguishment of debt			3,885			8,924
Gain on sale of business			—			(59,143)
Contingent consideration			—			(3,000)
Other non-routine, net			15,339			3,164
Adjusted EBITDA		$	1,071,051		$	934,165

Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) (unaudited and amounts in thousands, except share and per share amounts)
		Three Months Ended March 31,
		2022			2021
Net income (loss)		$	7,090		$	(13,090)
Amortization expense resulting from acquisition method adjustments			125,231			117,362
EBITDA adjustments			51,228			74,132
Tax effect of EBITDA adjustments and amortization expense			(53,254)			(44,413)
Adjusted net income (loss)		$	130,295		$	133,991
Adjusted net income (loss) per diluted share		$	0.39		$	0.42

		Year Ended March 31,
		2022			2021
Net income (loss)		$	(57,390)		$	(112,210)
Amortization expense resulting from acquisition method adjustments			498,843			463,334
EBITDA adjustments			257,491			243,947
Tax effect of EBITDA adjustments and amortization expense			(204,745)			(166,324)
Adjusted net income (loss)		$	494,199		$	428,747
Adjusted net income (loss) per diluted share		$	1.53		$	1.34

Segment Results (unaudited and amounts in thousands)
		Three Months Ended March 31,						$			%
		2022			2021			Change			Change
Segment revenue
Software and Analytics		$	443,171		$	416,265		$	26,906		6.5	%
Network Solutions			216,402			198,334			18,068		9.1	%
Technology-Enabled Services			234,262			227,311			6,951		3.1	%
Postage and Eliminations (1)			26,296			23,391			2,905		12.4	%
Purchase Accounting Adjustment (2)			—			(10,141)			10,141		(100.0	)%
Net revenue		$	920,131		$	855,160		$	64,971		7.6	%
Segment adjusted EBITDA
Software and Analytics		$	164,180		$	144,025		$	20,155		14.0	%
Network Solutions			103,170			108,147			(4,977)		(4.6	)%
Technology-Enabled Services			14,973			19,873			(4,900)		(24.7	)%
Postage and Eliminations			—			—			—		—	%
Total adjusted EBITDA		$	282,323		$	272,045		$	10,278		3.8	%

		Year Ended March 31,						$			%
		2022			2021			Change			Change
Segment revenue
Software and Analytics		$	1,612,931		$	1,534,926		$	78,005		5.1	%
Network Solutions			868,425			717,843			150,582		21.0	%
Technology-Enabled Services			924,472			869,349			55,123		6.3	%
Postage and Eliminations (1)			82,727			96,533			(13,806)		(14.3	)%
Purchase Accounting Adjustment (2)			(7,740)			(128,230)			120,490		(94.0	)%
Net revenue		$	3,480,815		$	3,090,421		$	390,394		12.6	%
Segment adjusted EBITDA
Software and Analytics		$	561,994		$	526,129		$	35,865		6.8	%
Network Solutions			446,378			377,005			69,373		18.4	%
Technology-Enabled Services			62,679			31,031			31,648		102.0	%
Postage and Eliminations			—			—			—		—	%
Total adjusted EBITDA		$	1,071,051		$	934,165		$	136,886		14.7	%

(1)	Revenue for Postage and Eliminations includes postage revenue of $60.9 million and $50.9 million for the three months ended March 31, 2022 and 2021, respectively. Revenue for Postage and Eliminations includes postage revenue of $219.6 million and $196.5 million for the years ended March 31, 2022 and 2021, respectively.
(2)	Amount reflects the impact to deferred revenue resulting from the McKesson exit which reduced revenue recognized during the three months ended March 31, 2021 as well as the years ended March 31, 2022 and 2021.

Reconciliation of Cash Provided by (Used in) Operating Activities to Free Cash Flow and Adjusted Free Cash Flow (unaudited and amounts in thousands)
		Year Ended March 31,
		2022			2021
Cash provided by (used in) operating activities (1)		$	696,878		$	586,196
Capital expenditures			(276,276)			(246,381)
Free cash flow			420,602			339,815
Adjustments to free cash flow (2):
Integration and related costs			26,803			40,675
Strategic initiatives, duplicative and transition costs			46,041			21,841
Severance costs			10,178			13,184
Integration and strategic capital expenditures			26,166			14,379
Adjusted free cash flow		$	529,790		$	429,894

(1)	Includes cash provided by pass-thru funds of $12.9 million for the year ended March 31, 2022 and cash used by pass-thru funds of $12.8 million for Change Healthcare Inc. for the year ended March 31, 2021.
(2)	All operating costs and integration and strategic capital expenditures are presented on an as-incurred basis.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005117/en/

David Elliott

Enterprise Strategy & Investor Relations

205-907-5540

daelliott@changehealthcare.com

Katherine Wojtecki

External Communications

630-624-9142

Katherine.Wojtecki@changehealthcare.com

Source: Change Healthcare Inc.

FAQ

What were Change Healthcare's total revenues for Q4 2022?

Change Healthcare reported total revenues of $920 million for Q4 2022.

How much did Change Healthcare's solutions revenue increase in Q4 2022?

Solutions revenue increased by 6.8% to $859.2 million in Q4 2022.

What is Change Healthcare's net income for Q4 2022?

The company reported a net income of $7.1 million for Q4 2022.

What is the status of the merger between Change Healthcare and OptumInsight?

The merger is awaiting regulatory approval and is subject to litigation pending completion.

What was the free cash flow for Change Healthcare in fiscal 2022?

The free cash flow for Change Healthcare in fiscal 2022 was $420.6 million, a 23.8% increase from the previous year.